



## Protective Effects of Infliximab on Indomethacin-Induced Gastric Ulcer in Rats: The Role of MAPK/NF- $\kappa$ B p65 Signaling Pathway

Hend R. Abd-Ellatif <sup>1\*</sup>, Gellan A.M. Kamel <sup>1</sup>, Azza A. Ali <sup>1</sup>

<sup>1</sup> Department of Pharmacology and Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt

\* Correspondence: [hendreda@azhar.edu.eg](mailto:hendreda@azhar.edu.eg)

Article history: Received: 11-04-2023

Revised: 19-08-2023

Accepted: 01-12-2023

**Abstract:** Nearly 25% of gastric ulcer (GU) instances globally are induced via nonsteroidal anti-inflammatory drugs (NSAIDs). Infliximab (Inflix), a monoclonal antibody, is widely utilized to medicate autoimmune disorders and chronic inflammatory disorders. This investigation aimed to determine if Inflix could prevent indomethacin (IND)-induced GU while examining potential protective mechanisms, such as the NF- $\kappa$ B/MAPK signaling pathway. Male albino rats received Inflix (5 and 7 mg/kg, intraperitoneally) on the fifth day, fasted for 24 h, and were exposed to IND (100 mg/kg, orally) for ulcer induction on the eighth day. The study showed that IND caused GU in macroscopic and histopathological manifestations. Pretreatment with Inflix improved gastric tissue damage in histopathological and macroscopic manifestations in a dose-dependent manner. Moreover, Inflix pretreatment increased the IND-affected decline in stomach prostaglandin E2 (PGE2) levels. Additionally, Inflix exerted antioxidant, anti-inflammatory, and anti-apoptotic effects by lowering oxidative stress markers, pro-inflammatory markers, and apoptotic markers in a dose-dependent approach. It was demonstrated that Inflix reduced the mitogen-activated protein kinase (MAPK) and the nuclear factor kappa B (NF- $\kappa$ B) p65 induced by IND-induced GU. Inflix exerts a gastro-protective effect via antioxidant, anti-inflammatory, and anti-apoptotic actions, which could be associated with modulating the NF- $\kappa$ B and MAPK cascades.

**Keywords:** Gastric ulcer, Indomethacin, Infliximab, TNF- $\alpha$ , NF- $\kappa$ B, MAPK

This is an open access article distributed under the CC BY-NC-ND license <https://creativecommons.org/licenses/by/4.0/>

### 1. INTRODUCTION

Gastric ulcer (GU) represents a popular digestive syndrome that refers to the presence of ulcers in the stomach <sup>1,2</sup>. One of the most frequent causes of ulcer development is the improper utilization of nonsteroidal anti-inflammatory drugs (NSAIDs) <sup>3</sup>. NSAIDs are non-selective cyclooxygenase enzyme inhibitors that hinder cyclooxygenase enzymes 1 (COX-1) and 2 (COX-2) and have antipyretic, analgesic, and anti-inflammatory impacts <sup>4, 5</sup>. Among the frequently utilized NSAIDs, indomethacin (IND) has a potent ulcerogenic possibility in humans <sup>6, 7, 8</sup>. It is well acknowledged that IND administration probably increases the reactive oxygen species (ROS) <sup>9, 10</sup> causing oxidative stress that damage the gastric mucosa, which results in GU <sup>9, 16, 17</sup>. Superoxide anion radicals, hydrogen peroxide, and hydroxyl radicals' generation, all of these factors induce lipid

peroxidation <sup>3,11</sup>. Malondialdehyde (MDA) is one of the crucial byproducts of membrane lipid peroxidation <sup>12, 13</sup>, whereas superoxide dismutase (SOD) acts a critical anti-oxidative function that dismutates superoxide radicals into harmless molecules (O<sub>2</sub>) <sup>14, 15</sup>.

Pro-inflammatory cytokine release may be triggered by IND, including tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-1 beta (IL-1 $\beta$ ), and interleukin-6 (IL-6), resulting from the epithelial barrier's rupture <sup>18,19</sup>. Pro-apoptotic mediators are also activated via IND administration. IND can also impede the healing of GU by inhibiting prostaglandin production, particularly PGE2 <sup>21</sup>, which has gastroprotective anti-inflammatory properties. Caspases including caspase-3 (Casp-3) are pro-apoptotic proteolytic enzymes that are either activated by the intrinsic mitochondrial system or by the extrinsic death receptor pathways, mediating apoptotic cell death <sup>8, 16</sup>. MAPKs are major

intracellular signal transduction pathways<sup>17, 20</sup>. P38, c-jun-n-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK), are the active subunits from the MAPKs activation<sup>22-26</sup>. The stimulated MAPK cascade activates the NF- $\kappa$ B cascade<sup>12</sup>. Moreover, NF- $\kappa$ B reacts immediately to stress and inflammatory responses and is crucial for the pathogenesis of GU<sup>27</sup>. ROS and pro-inflammatory chemicals are created either directly or through the activation of the MAPKs/NF- $\kappa$ B cascade<sup>28, 29</sup>. TNF- $\alpha$ , IL-1 $\beta$  and IL-6, are the products of the MAPKs/NF- $\kappa$ B signaling transduction cascade<sup>12, 27, 30</sup>.

Infliximab (Inflix) is a monoclonal antibody that is used therapeutically to treat Crohn's disease (CD), rheumatoid arthritis (RA), and dermatological diseases<sup>25, 33, 34</sup>. It was mentioned to scavenges oxygen free radicals and hinder inflammation by its modulating effect on the TNF- $\alpha$  receptor<sup>35, 36</sup>. Additionally, Inflix may prevent inflammation via the MAPK/ NF- $\kappa$ B signaling pathway<sup>20, 25</sup>. It is thought that TNF- $\alpha$  binds to its receptor and activates several signaling pathways, including JNK, MAPK, ERK, and NF- $\kappa$ B. After that, many transcription factors will be activated, resulting in the various proteins' transcription related to the inflammatory reactions and other consequences<sup>37-42</sup>.

No beneficial strategies are available for complete ulcer healing<sup>31</sup>. The most effective choice to protect against NSAID-related GU toxicity is either the combination of NSAIDs and proton pump inhibitors (PPIs)<sup>31</sup> or the selective COX-2 inhibitors' choice<sup>32</sup>. There are numerous severe side effects related to the long-term utilization of anti-ulcer medications. Gastric ulcer patients frequently stop using the medication due to adverse effects. As a result, patients require novel therapies<sup>8</sup>. We hypothesized that Inflix might attenuate IND-induced GU by preventing TNF- $\alpha$  induced inflammations by regulating the MAPK/NF- $\kappa$ B signaling cascade.

## 2. METHODS

### 2.1. Animals

The Nile Company for Pharmaceuticals and Chemical Industries' animal facility provided forty adult male albino rats considering 180 and 200 g (Cairo, Egypt). The experimental animals received frequent feedings and free access to water while maintaining 55% humidity, a constant temperature of  $25 \pm 2$  °C, and a 12-hour light/dark cycle. Before any experimental procedures, animals had a one-week acclimatization period. The research methods were done in line with the Animal Ethics Committee's recommendations of the Faculty of Pharmacy at Al-Azhar University in Egypt and the eighth edition of

the NRC Instructions for the Care and Use of Laboratory Animals (permission number: 203/2019).

### 2.2. Medicines and chemicals

The chemicals were obtained from Sigma-Aldrich and were of highly analytical quality (St. Louis, MO, USA). The pharmaceutical and chemical sectors (El-Nile Co., Cairo, Egypt) provided vials of IND (Liometacen®), which contained the active ingredient meglumine (77.2 mg) and was equivalent to 50 mg of IND. For the pharmaceutical and chemical industries, esomeprazole (Esmorap®) vials containing esomeprazole 40 mg sodium salt were gotten from AUG Pharma (Cairo, Egypt). Infliximab (Remicade®) was provided as vials (infliximab 100 mg powder for concentrate) from Schering-Plough Labo for the pharmaceutical and chemical industries (Cairo, Egypt).

### 2.3. Ulcer induction

Animals have fasted for 24 hours with free access to water. Gastric ulceration of rats was induced by giving a single oral dose of indomethacin IND (100mg/kg). Gastric ulceration was detected after 6 hrs of IND administration<sup>43, 44</sup>.

### Experimental design

Fourty male albino rats weighing (180g - 200g) divided into 5 groups (eight per group) and regimen treatments as follow below and demonstrated in Figure 1:


**Group I:** rats received saline (1ml/kg/daily, p.o.) from 1st day until the end of experiment (8 days) as control-group.

**Group II:** rats received saline (1ml/kg/daily, p.o.) from 1st day until the 7<sup>th</sup> day. They fasted first for 24 hrs before IND administration with access to water. In the day of scarification (the 8th), rats received IND (100mg/kg, p.o.) and after 6 hrs, they were killed for examination as IND group<sup>45</sup>.

**Group III:** rats received Esmo (50mg/kg/daily, i.p.) as Esmo group<sup>20</sup> from 1<sup>st</sup> day until the 7<sup>th</sup> day. In the 7<sup>th</sup> day, they fasted for 24 hrs then received IND (100mg/kg, p.o.).

**Group VI:** rats received Inflix 5mg/kg (i.p.) as Inflix 5mg group only in the 5th day of the experiment<sup>46</sup>. In the 7<sup>th</sup> day, they fasted for 24 hrs then received IND (100mg/kg, p.o.).

**Group V:** rats received Inflix 7mg/kg (i.p.) as Inflix 7mg group only in the 5<sup>th</sup> day of the experiment<sup>46</sup>. In the 7<sup>th</sup> day, they fasted for 24 hrs then received IND (100mg/kg, p.o.).



**Figure 1:** Schematic of study design.

To assess serum TNF- $\alpha$ , IL-1 $\beta$ , and IL-6 level, blood specimens were taken through retro-orbital sinus puncture under mild ether anesthesia six hours after the ulcer was induced. After the animals were killed, the stomach tissues of the rats were removed, cleaned with saline, and examined under a microscope. The stomach tissues were then weighed. For histological investigation, two distinct stomach tissues were embedded in a 10% formalin solution. 10% (w/v) tissue homogenates in ice-cold phosphate-buffered saline were made from three stomach tissues for biochemical analysis. The centrifugation of homogenates occurred at 4 °C for 15 min at 4000 rpm. Until the oxidative stress markers, pro-inflammatory biomarkers, and PGE2 examination, the acquired supernatant was preserved at -80 °C. Further three stomach tissues were kept at - 80 °C and homogenized in lysis buffer for a western blot assay of apoptotic markers (BAX, BCL-2, and casp-3), the MAPK pathway (p-MAPK, p-ERK, and p-JNK), and p-NF- $\kappa$ B P65 cascade.

#### 2.4. Macroscopic evaluation

The stomachs were opened along the greater curvature, rinsed with saline to remove gastric contents and blood clots and examined by a 10X magnifier lens to assess the formation of ulcers. The numbers of ulcers were counted. Scoring of ulcer will be made as follows <sup>48</sup>:

- Normal colored stomach..... (0)
- Red coloration..... (0.5)
- Spot ulcer..... (1)
- Hemorrhagic streak... (1.5)
- Deep Ulcers..... (2)
- Perforation..... (3)

#### 2.5. Histopathological evaluation

Specimens of the stomach were embedded in paraffin, fixed in 10% formalin, and stained with hematoxylin and eosin after being sectioned into 4  $\mu$ m thick pieces <sup>49</sup>.

#### 2.6. Biochemical parameters

##### 2.6.1. Determination of oxidative stress biomarkers

Utilizing kits purchased from Biodiagnostic Co., Egypt, stomach homogenates were utilized to estimate the lipid peroxides' number generated as SOD, total antioxidant capacity (TAC), and MDA. The stages were done per the manufacturer's guidelines, and the parameters were calculated according to the guidelines.

##### 2.6.2. Determination of pro-inflammatory biomarkers

An ELISA kit (CUSABIO, USA) was utilized to determine the IL-6, IL-1 $\beta$ , and TNF- $\alpha$  level in the stomach and serum. The manufacturer's protocol was followed in accordance with the guidelines for each parameter that was tested, and concentration samples were measured per the manufacturer's instructions.

##### 2.6.3. Determination of gastric PGE2

Using an ELISA kit purchased, gastric PGE2 was measured (CUSABIO, USA). The manufacturer's protocol was implemented in accordance with the guidelines for each parameter that was tested, and concentration samples were measured in line with the manufacturer's guidelines.

2.6.4. Western blot analysis for determination of gastric apoptotic markers (BAX, BCL-2, and casp-3) and MAPK and NF-κB P65 pathways

The stomach tissue was homogenised in a lysis solution involving 50 mM Tris-Cl, 0.5% Triton X-100, 300 mM NaCl, and a protease inhibitor, which also had a pH of 7.5. After that, the buffer was incubated for 30 minutes at 4 °C. At 4 °C, the lysates were spun for 20 minutes at 15,000 rpm. 30 g of proteins were put onto a 10% SDS/PAGE to evaluate the protein concentrations utilising the Bradford protein assay reagent (Bio-Rad, USA). The membrane was rinsed twice in TBS-0.05% Tween-20 (TBS-T) before being blocked for an hour in 5% skimmed milk powder after the gels had been transferred to nitrocellulose membranes and each antibody had been applied. Then, primary antibodies for apoptotic markers for BAX, BCL-2, and casp-3 and P-MAPK, P-ERK, P-JNK, and P-NF-κB P65 were incubated overnight on the membranes (1:2000 Cell Signaling Technology) at 4 °C. The membrane was then exposed to an anti-mouse secondary antibody at 37 °C for one hour and rinsed five times for five minutes in TBS-T (dilution 1:5000, CST, USA). The blot was TBST-washed three to five times for five minutes. The chemiluminescent substrate (Clarity™ Western ECL substrate) was incorporated to the blot in line with the manufacturer's instructions. Using a CCD camera-based imager, the chemiluminescent signals were captured. After protein normalisation on the ChemiDoc MP imager, the target proteins' band intensities were contrasted with the control specimen's β-actin utilising image analysis software.

2.7. Statistical analysis

Means ± SEM were used to display the data. The results were statistically analysed utilising one-way ANOVA and post hoc Tukey's multiple comparison assays utilising GraphPad Prism software (version 8). Values of p ≤ 0.05 and 0.005 were statistically substantial for all analyses.

3. RESULTS

3.1. Macroscopic examination of the stomach

Macroscopic examination of stomach from control group revealed no lesions but there were a presence of slight red coloration. While stomach from IND group revealed the presence of hemorrhagic streaks and deep ulcer. Esmo pretreatment revealed presence of red coloration, spot ulcer and less deep ulcer compared to IND group. Pretreatment with Inflix 5 and 7mg revealed presence of red coloration, spot ulcer and less deep ulcer compared to IND group as demonstrated in Figure 2.

Effect of Inflix on the ulcer score in IND-induced GU in rats

Contrasted to the control group, IND administration made a statistically significant elevation in lesions with a score of 4± 0.37 (Table 1). Pretreatment with Esmo significantly decreased lesions with a score of 1.5± 0.22 contrasted to the IND group. Inflix 5 mg and 7 mg pretreatment significantly decreased lesions with a score of 1.5± 0.22 and 1.33± 0.21, respectively, compared to the IND group.

Table 1: Effect of infliximab (Inflix) on the ulcer score in indomethacin-treated rats

Groups/Parameters	Ulcer score
Control group	0.08±0.08
IND group	4±0.37**
Esmo +IND	1.5±0.22**##
Inflix 5mg+IND	1.5±0.22**##
Inflix 7mg+IND	1.33±0.21**##

\*\*p ≤ 0.005, significant difference compared with control

##p ≤ 0.005, significant difference compared to IND

Values mean ± SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo: esomeprazole and Inflix: infliximab.

3.2. Effect of Inflix on histopathological alterations in IND-induced GU in rats

A histopathology investigation was conducted to further support Inflix's stomach protective function. Rat-control stomach slices stained with H&E revealed normal histopathological structure during microscopic examination (Fig.3.A). IND administration caused focal ulceration with hemorrhage and hemosiderosis in the mucosal layer linked with inflammatory cell infiltration and edema in the underlying submucosal layer (Fig.3.B).


Pretreatment with Esmo resulted in edema with a few inflammatory cells infiltrating the submucosal layer (Fig.3.C). Inflix 5 mg pretreatment showed focal necrosis in the mucosal layer, while the underlying submucosa had edema with inflammatory cell infiltration (Fig.3.D). Inflix 7 mg group pretreatment showed edema in the submucosal layer with focal inflammatory cell infiltration (Fig.3.E).

3.3. Effect of Inflix on gastric oxidative stress biomarkers in IND-induced GU in rats

Ulcer induction by IND significantly elevated MDA by 462% contrasted to the control group and significantly lowered SOD and TAC by 18% and 38%, consecutively, contrasted to the control group (Table 2). Pretreatment with Esmo decreased MDA by 43% compared to IND group and significantly increased SOD and TAC by 322% and 217%, respectively, compared to IND group. Pretreatment with Inflix 5 mg significantly decreased MDA levels by 54% compared to IND group. It significantly


increased SOD and TAC by 521% and 212%, respectively, compared to IND group. Pretreatment with Influx 7 mg significantly diminished MDA level

by 27% contrasted to the control group and considerably increased SOD and TAC by 546% and 231%, respectively, compared to IND.



**Figure 2:** Macroscopic appearance of rat stomach.

(A–E) Macroscopic images of the stomach. (A) normal stomach (control), (B) ulcer induced in the stomach using IND, (C) pretreatment of stomach by Esmo 50 mg/kg before IND treatment, (D) pretreatment of stomach by Influx 5 mg before IND treatment, (E) pretreatment of stomach by Influx 7mg before IND treatment. Abbreviation: IND: indomethacin, Esmo: esomeprazole, Influx: infliximab.



**Figure 3:** Effect of Influx on histopathological changes on IND-induced GU in rats

Microscopic examination of H&E-stained stomach sections of control rats showed normal histopathological structure (Fig.3.A). IND administration caused focal ulceration with haemorrhage and hemosiderosis in mucosal layer associated with oedema and inflammatory cells infiltration in the underlying submucosal layer (Fig.3.B). Pretreatment with Esmo Showed oedema with few inflammatory cells infiltration in the submucosal layer (Fig.3.C). Influx 5mg pretreatment showed Focal necrosis in the mucosal layer while the underlying submucosa had oedema with inflammatory cells infiltration (Fig.3.D). Influx 7mg group pretreatment showed oedema in the submucosal layer with focal inflammatory cells infiltration (Fig.3.E). Abbreviation: mu : mucosa, subm : submucosa, ulc : ulcer, o : oedema, nc : necrosis, m arrow: inflammatory cell infiltration.

**Table 2:** Effect of Influx on gastric SOD, gastric MDA and gastric TAC levels in indomethacin-treated rats

Groups/Parameters	SOD (U/g)	MDA (nmol/g)	TAC activity
Control group	55.52±3.16	27.92±0.41	105.9±1.42
IND group	12.58±0.67**	117.4±1.13**	47.9±1.95**
Esmo group +IND	29.93±1.03***	59.28±2.10****	90.67±2.00****
Inflix 5mg +IND	46.73±1.50***	66.97±2.28****	82.81±2.30****
Inflix 7mg +IND	49.77±2.77##	40.98±2.81****	94.8±0.64****


\*p ≤ 0.05, significant difference compared with control, \*\*p ≤ 0.005, significant difference compared with control, ##p ≤ 0.005, significant difference compared to IND, Values mean ± SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo: esomeprazole, Influx: infliximab, SOD: superoxide dismutase, MDA: Malondialdehyde and TAC: Total antioxidant capacity.

**3.4. Effect of Influx on gastric pro-inflammatory biomarkers in IND-induced GU in rats**

Ulcer induction by IND significantly elevated gastric TNF-α, IL-1β, and IL-6 via 541%, 256%, and 309%, consecutively, compared to the control group (Fig. 4 A, B, C). Esmo pretreatment substantially reduced gastric TNF-α, IL-1β, and IL-6 by 49%, 56%, and 51%, respectively, compared to IND group. Pretreatment with Influx 5 mg significantly lowered gastric TNF-α, IL-1β, and IL-6 by 38%, 55%, and 52%, respectively, contrasted to IND group. Influx 7 mg pretreatment considerably decreased gastric IL-1β, TNF-α, and IL-6 by 36%, 46%, and 40%, consecutively, contrasted to IND group.


**3.5. Effect of Influx on serum pro-inflammatory biomarkers in IND-induced GU in rats**

Ulcer induction by IND significantly elevated serum TNF-α, IL-1β, and IL-6 via 613%, 291%, and 376%, consecutively, compared to control group (Fig. 5A, B, C). Pretreatment with Esmo significantly lowered serum TNF-α, IL-1β, and IL-6 via 49%, 49%, and 40%, consecutively, contrasted to IND group. Pretreatment with Influx 5 mg significantly lowered serum TNF-α, IL-1β, and IL-6 by 42%, 51%, and 54%, consecutively, contrasted to IND group. Pretreatment with Influx 7 mg significantly reduced serum TNF-α, IL-1β, and IL-6 via 31%, 44%, and 38%, consecutively, contrasted to IND group.



**Figure 4:** Effect of Influx on gastric pro-inflammatory biomarkers in on IND-induced GU in rats

\*\*p ≤ 0.005, significant difference compared with control, ##p ≤ 0.005, significant difference compared to IND, Values mean ± SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo: esomeprazole, Influx: infliximab, TNF-α: tumor necrosis factor –alpha, IL-1β: interleukin 1 beta and IL-6: interleukin 6.



**Figure 5:** Effect of Influx on serum pro-inflammatory biomarkers on IND-induced GU in rats

\*\*p ≤ 0.005, significant difference compared with control, ###p ≤ 0.005, significant difference compared to IND, Values mean ± SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo: esomeprazole, Influx: infliximab, TNF-α: tumor necrosis factor -alpha, IL-1β: interleukin 1 beta and IL-6: interleukin 6.

### 3.6. Effect of Influx on Gastric PGE2 in IND-induced GU in rats

Concerning the control group, IND significantly lowered the PGE2 level by 35%. Pretreatment with Esmo, Influx 5 mg and Influx 7 mg significantly increased the level of PGE2 by 188%, 195%, and 230%, respectively, contrasted to the IND group (Table 3).

**Table 3:** Effect of Influx on gastric PGE2 levels in indomethacin-treated rats

Groups/Parameters	PGE2 level (pg/ml)
Control group	22.77±0.42
IND group	8.85±0.08**
Esmo Group +IND	17.68±0.34###
Inflix 5mg+IND	16.77±0.95###
Inflix 7mg+IND	18.17±0.50###

\*\*p ≤ 0.005, significant difference compared with control , ##p ≤ 0.005, significant difference compared to IND, Values mean ± SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo: esomeprazole, Influx: infliximab and PGE2: Prostaglandin E2

### 3.7. Effect of Influx gastric apoptotic markers in IND-induced GU in rats

Ulcer induction by IND significantly increased BAX and casp-3 by 663% and 530%, respectively, contrasted to the control group, and significantly lowered BCL-2 via 15% with respect to the control group (Fig. 6 A, B, C). Pretreatment with Esmo significantly decreased BAX and casp-3 by 40% and 40%, respectively, compared to IND group, and significantly increased BCL-2 by 546% compared to IND group. Pretreatment with Influx 5 mg


significantly decreased BAX and casp-3 by 35% and 28%, respectively, compared to IND group and significantly increased BCL-2 by 553% contrasted to IND group. Pretreatment with Influx 7 mg significantly decreased BAX and casp-3 by 24% and 24%, respectively, compared to IND group and significantly elevated BCL-2 by 593% compared to IND group.

### 3.8. Effect of Influx on Mitogen-Activated Protein Kinase (MAPK) cascade expression in IND-induced GU in rats

As illustrated in Figure 7, immunoblotting revealed that P-MAPK, P-ERK and P-JNK expression levels were increased in the IND group by 725%, 485%, and 524% concerning the control group, respectively. However, Esmo, Influx 5 mg and Influx 7 mg pretreatment decreased P-PMAPK, P-ERK, and P-JNK protein levels by (47%, 42%, and 32%), (47%, 51%, and 30%), and (51%, 49% and 38%) with respect to the IND group, consecutively.


### 3.9. Effect of Influx on Nuclear Factor kappa B (NF-κB) cascade expression in IND-induced GU in rats

As illustrated in Figure 8, immunoblotting revealed that P-NF-κB P65 expression levels were increased in the IND group by 713% regarding the control group. However, Esmo, Influx 5 mg and Influx 7 mg pretreatment decreased P-NF-κB P65 protein levels via (42%, 38%, and 28%) compared to the IND group.




**Figure 6:** Effect of Inflix on apoptotic factors on IND-induced GU in rats

\* $p \leq 0.05$ , significant difference compared with control, \*\* $p \leq 0.005$ , significant difference compared with control, \*\*\* $p \leq 0.005$ , significant difference compared to IND, Values mean  $\pm$  SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo: esomeprazole, Inflix: infliximab, BAX: Bcl-2 associated x, BCL-2: B-cell lymphoma 2 and casp-3: cleaved caspase-3.



**Figure 7:** Effect of Inflix on MAPK pathway on IND-induced GU in rats

\*\* $p \leq 0.005$ , significant difference compared with control, \*\*\* $p \leq 0.005$ , significant difference compared to IND, Values mean  $\pm$  SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo group: esomeprazole, Inflix: infliximab, MAPK: mitogen activated protein kinase, ERK: extracellular-signal-regulated kinase and JNK: c-jun N-terminal kinase.



**Figure 8:** Effect of Influx on NF-kB pathway on IND-induced GU in rats

\*\*p ≤ 0.005, significant difference compared with control, \*\*\*p ≤ 0.005, significant difference compared to IND, Values mean ± SEM (n=8). Utilizing one-way analysis of variance (ANOVA) accompanied by Turkey-Kramer test for multiple comparisons. Abbreviation: IND: indomethacin, Esmo: esomeprazole, Influx: infliximab, and NF-kB Nuclear Factor kappa B.

#### 4. DISCUSSION

GU is one of the most prevalent disorders impacting the quality of life<sup>50</sup>. When hostile factors gain the upper hand over protective factors, they lead to ulcers and tissue damage<sup>51</sup>.

NSAIDs cause damage to the stomach by inhibiting COX-1, COX-2, and PGE2 (52). According to previous research, the action of IND on PG synthesis is linked to the free radicals' production in ulcerated gastric tissues<sup>53</sup>.

Influx is a monoclonal antibody that works as a free radical scavenger and inflammation inhibitor. Influx may also prevent TNF-α influenced inflammation via the NF-κB and MAPK signaling cascades<sup>54</sup>. It has proven effective in treating many diseases, such as ulcerative colitis<sup>55</sup>.

A macroscopic examination of the stomach was used to assess ulcer formation and the scoring of ulcers. This study supported the hypothesis that IND causes ulcers, proven by the ulcer score. The possible explanation is that gastric damage can easily be produced by forming endogenous and exogenous ROS and free radicals. This finding agrees with previous research<sup>3</sup>. Our findings demonstrated that pretreatment with Esmo decreased the ulcer score contrasted to ulcer-induced rats, which is in harmony with a prior study<sup>20</sup>. The current research aimed to determine how Influx at 5 and 7 mg doses affected IND-induced GU. Data from the present work indicated that Influx 5 and 7 mg pretreatment significantly decreased the ulcer score contrasted to IND group. This finding agrees with those of (Freitas et al., 2022), who reported that Influx decreased the acute inflammatory process in oral ulcers.

In this study, the stomach of the IND group showed the presence of hemorrhagic streaks and deep ulcers. In contrast, Esmo pretreatment showed fewer ulcer numbers compared to IND group, which

aligns with a previous result by (El Badawy et al., 2021). The present results showed that pretreatment with Influx 5 and 7 mg resulted in fewer ulcers as compared to IND group. That agrees with previous research analyzing the Influx's protective impacts in a rat model of IND-induced enterocolitis<sup>18</sup>.

Hematoxylin-eosin stain was used to evaluate the stomach histopathological modifications' extent in rats. The ongoing study observed that ulcer induction by IND caused focal ulceration with hemorrhage and hemosiderosis in gastric mucosal layer, and submucosal edema, and inflammatory cell infiltration, and these outcomes agree with some changes reported in earlier research<sup>58</sup>. In these results, pretreatment with Esmo improved the pathophysiological changes produced by IND, which constitutes the result conducted by researchers<sup>59</sup>. The ongoing work also indicated that all pathophysiological alterations produced by IND were enhanced by pretreatment with Influx, but to different extents. This result agrees with some changes reported in a previous study, which showed that Influx pretreatment decreased hemorrhagic areas and inflammatory cell infiltration in lung tissues<sup>36</sup>.

It is well defined that the pathogenesis of IND-induced gastric lesions involves the generation of ROS that may have a significant role, namely due to lipid peroxide generation, accompanied by impairment of enzyme activity of the cell<sup>9</sup>. SOD is considered the defense's first line versus the harmful impact of ROS on cells<sup>74</sup>. One of the secondary lipid peroxidation products is MDA, and it can be utilized as a sign of damage to cell membranes<sup>75, 76</sup>. The imbalance between pro- and antioxidant molecules leads to oxidative stress<sup>77</sup>. In the current research, IND significantly decreased SOD and TAC activity and increased MDA levels, leading to oxidative stress. A similar pattern was previously recorded<sup>16, 45</sup>. Pretreatment with Esmo caused a significant elevation in SOD and TAC actions and a decline in MDA levels with regard to IND group. This finding

agrees with prior research <sup>78, 79</sup>. In this study, pretreatment with Influx 5 and 7 mg demonstrated a significant elevation in SOD concerning IND, which aligns with a study by (Abdelrahman et al., 2018). The present study showed that Influx 5 and 7 mg pretreatment influenced a significant reduction in MDA content with regard to IND group. This outcome agrees with those who reported that Influx medication of stressed rats significantly switched the elevation in MDA content <sup>81</sup>. In this study, Influx 5 and 7 mg pretreatment induced a significant decline in TAC content with regard to the IND group. This result aligns with previous research <sup>80</sup>.

Cytokines regulate the mucosal immune defense, including TNF- $\alpha$ , IL-1 $\beta$ , and IL-6, <sup>60-64</sup>. Dysregulation of TNF- $\alpha$  production and other cytokines has been linked with different human diseases, including GU <sup>65</sup>. IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , expressions were significantly raised by IND in this study with regard to the control group. This outcome aligns with prior research <sup>58, 66, 67</sup>. Pretreatment with Esmo significantly reduced TNF- $\alpha$ , IL-1 $\beta$ , and IL-6, level that is similar to previous studies <sup>68, 69</sup>. Our outcomes demonstrated that pretreatment with Influx demonstrated a significant reduction in TNF- $\alpha$ , IL-1 $\beta$ , and IL-6 level, compared to ulcer-induced rats in a dose dependent manner which agrees with the findings by (Onda et al., 2004; Danese et al., 2006; Poutoglidou et al., 2021; Senousy et al., 2022).

PGE2 can elevate gastric blood flow, stimulate mucus and bicarbonate secretion, hinder acid secretion <sup>90</sup>, and even inhibit neutrophil-mediated free radical generation <sup>91, 92</sup>. The ongoing research demonstrated that IND induced a significant decrease in PGE2 regarding the control group, which agrees with previous research <sup>93</sup>. Pretreatment with Esmo significantly increased PGE2 with respect to IND groups <sup>94</sup>. The observed elevation in PGE2 levels in groups pretreated with Influx is in line with a prior study <sup>47</sup>. We concluded from these studies that Influx has an anti-inflammatory effect and can easily increase the protective PGE2.

Bax and casp-3, which promote apoptosis when mitochondria are damaged, are crucial in disrupting stomach mucosal integrity. Activating casp-3, the apoptosis' executor, causes programmed cell death. Bcl-2 inhibits Bax's activation and apoptosis <sup>19, 82, 83</sup>. In this study, ulcer induction by IND generated a significant boost in Bax and casp-3 and a reduction in Bcl-2 concerning the control group. Alike pattern was computed previously <sup>21, 84</sup>. Pretreatment with Esmo stimulated a significant reduction in Bax and casp-3 content and an elevation in Bcl-2 content with respect to the IND group, and this result agrees with previous studies by (Ogaly et al., 2021; Taskiran et al., 2021). This study showed that pretreatment with Influx induced a significant reduction in Bax and

casp-3 content and an elevation in Bcl-2 content with regard to the IND group. This result agrees with previous studies <sup>86-89</sup>.

The MAPK pathway can be activated by ROS or other inflammatory stimuli, such as ulcer induction by IND or stress. Total MAPK is converted to phosphorylated form then degraded to ERK, JNK, and p38. By causing I $\kappa$ B $\alpha$  to become phosphorylated and separate from the NF- $\kappa$ B p65 subunit, the p38, ERK, and JNK phosphorylation promotes the NF- $\kappa$ B p65 subunit's activation. Increasing the levels of TNF- $\alpha$ , IL-1 $\beta$ , and IL-6 are consequently controlling the several pro-inflammatory genes' expression, which cause tissue and cell inflammatory damage <sup>12, 22, 58, 61, 95-99</sup>.

The MAPK cascade was significantly active in the IND group in the current investigation, as predicted, and this finding aligns with other research <sup>58, 100</sup>. Esmo pretreatment lowered the production of the phosphorylated subunits of MAPK, ERK, and JNK. This outcome is consistent with a previous study <sup>101</sup>. Western blotting experiments in the current research demonstrated that the pretreatment with Influx significantly lowered the high levels of phosphorylation of JNK, MAPK, and ERK in the gastric epithelium stimulated via ulcer induction by IND, suggesting that Influx could dose-dependently inhibit P-MAPK, P-ERK, and P-JNK signaling pathways in IND-induced GU, which is similar to the finding obtained by cordaro et al. <sup>102</sup>.

Although it has long been assumed that I $\kappa$ B breakdown and NF- $\kappa$ B p65 nuclear translocation are necessary for NF- $\kappa$ B activation <sup>28, 103</sup>, TNF- $\alpha$  is also the main stimulator for NF- $\kappa$ B expression <sup>104, 105</sup>. Lately, it has been demonstrated that activating the MAPK cascade is essential for activating the NF- $\kappa$ B pathway. The NF- $\kappa$ B pathway was significantly active in the IND group in the current investigation, as predicted by the elevated level of ROS. This outcome is in line with a research that found that IND enhances the NF- $\kappa$ B cascade <sup>59</sup>. Esmo pretreatment lowered the production of the phosphorylated NF- $\kappa$ B p65 subunit. This result agrees with other research <sup>106-108</sup>. The extreme-dose pretreatment improved these impacts with Influx 7 mg. This outcome is consistent with (Dadsetan et al., 2016; Habib et al., 2019; Younis et al., 2021). The antioxidative effect of Esmo or Influx may inactivate the MAPK pathway, which weakens the phosphorylation of NF- $\kappa$ B p65, leading to a downregulated expression of TNF- $\alpha$  and IL-1 $\beta$ , simultaneously interfering the positive feedback of TNF- $\alpha$  and IL-1 $\beta$  to the ROS signaling pathways with the production of ROS and the cross-regulation of upstream signaling pathways.

## 5. CONCLUSIONS

This study shows that besides invasive factors, including stomach acid and pepsin, inflammatory damage produced by ROS is related to a cascade of activations of NF- $\kappa$ B signaling pathways and the MAPK pathway, which are crucial to the pathophysiology of GU. Mucosal damage is aggravated by the positive feedback loop between pro-inflammatory factors and ROS signaling cascades. The anti-inflammatory, anti-oxidative, and apoptotic actions of pretreatment with Esmo or Inflix protect rats from IND-induced GU (fig.9). We also showed that Inflix 7 mg had more significant effects on most of results compared to Esmo or Inflix 5 mg.

**Funding:** NA.

**Acknowledgments:** I would like to express my gratitude to my supervisors, who guided me throughout this project.

**Conflicts of Interest:** NA.

**Ethical Statement:** The Ethics Committee of the faculty of Pharmacy at Al-Azhar University in Egypt (permission number: 203/2019) was followed in all animal methods. Animal disturbance, pressure, and difficult manoeuvres were avoided.

**Author Contribution:** All authors contributed to all steps of work.

**List of Abbreviations:** ANOVA: Analysis of Variance, BAX: Bcl-2 associated X, BCL-2: B-cell lymphoma 2, Casp-3: Caspase-3, CD: Crohn's disease, COX-1: Cyclooxygenase-1, COX-2: Cyclooxygenase-2, ELISA: Enzyme Linked immunosorbent assay, ERK: Extracellular signal-regulated kinase, Esmo: Esomeprazole, GU: Gastric ulcer, IL-1 $\beta$ : Interleukin - 1beta, IL-6: interleukin-6, IND: Indomethacin, Inflix: Infliximab, I.p.: Intraperitoneal, JNK: C- jun-n- terminal kinase, MAPK: Mitogen-activated protein kinase, M arrow: Inflammatory cell infiltration, MDA: Malondialdehyde, Mu: mucosa, Nc: Necrosis, NF- $\kappa$ B p56: Nuclear factor kappa B Nuclear factor kappa B p56, NSAIDs: Non-steroidal anti-inflammatory drugs, O: Oedema, PGE2: Prostaglandin E2, P.o.: per oral, PPIs: Proton pump inhibitors, RA: Rheumatoid arthritis, ROS: Reactive oxygen species, SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis, SEM, Standard error of mean, SOD: Superoxide dismutase, Subm: Submucosa, TAC: Total antioxidant capacity, TBST: Tris buffered saline with tween, TNF- $\alpha$ : Tumor necrosis factor -alpha, Ulc, Haemorrhage.

## REFERENCES

1. Abd Al Haleem EN, Mohamed GA, Awad AS, Taha RA. Gastro-Protective Effects of Epigallocatechin 3-Gallate: Impact on Anti-oxidant, Anti-Inflammatory, and Anti-Apoptotic Actions,(In vivo and In vitro Study). *Sys Rev Pharm.* 2020;11(12):677-94.
2. Yim MH, Kim KH, Lee BJ. The number of household members as a risk factor for peptic ulcer disease. *Sci Rep.* 2021;11(1):1-10.
3. Boushra AF, Elsayed AM, Ibrahim NA, Abdelwahed MK, Ahmed EI. A comparative study on the possible protective effect of esomeprazole, spirulina, wheatgrass on indomethacin-induced gastric ulcer in male albino rats. *Molecul Biol Rep.* 2019;46:4843-60.
4. Gliszczynska A, Nowaczyk M. Lipid formulations and bioconjugation strategies for indomethacin therapeutic advances. *Molecules.* 2021;26(6):1576.
5. Huntjens D, Danhof M, Della Pasqua O. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. *Rheumatology.* 2005;44(7):846-59.
6. Adhikary B, Yadav SK, Roy K, Bandyopadhyay SK, Chattopadhyay S. Black tea and theaflavins assist healing of indomethacin-induced gastric ulceration in mice by antioxidative action. *Evid. Based Complementary Altern. Med.* 2010;2011.
7. Yadav SK, Adhikary B, Chand S, Maity B, Bandyopadhyay SK, Chattopadhyay S. Molecular mechanism of indomethacin-induced gastropathy. *Free Radic Biol Med.* 2012;52(7):1175-87.
8. Toktay E, Yayla M, Sahin L, Harmankaya A, Ozic C, Aksu Kilicle P, et al. The effects of dragon fruit (*Hylocereus polyrhizus*) extract on indomethacin-induced stomach ulcer in rats. *J Food Biochem.* 2022;46(9):e14274.
9. Jia Y-T, Wei W, Ma B, Xu Y, Liu W-J, Wang Y, et al. Activation of p38 MAPK by reactive oxygen species is essential in a rat

- model of stress-induced gastric mucosal injury. *The J Immunol.* 2007;179(11):7808-19.
10. Shian WM, Sasaki I, Kamiyama Y, Naito H, Matsuno S, Miyazawa T. The role of lipid peroxidation on gastric mucosal lesions induced by water-immersion-restraint stress in rats. *Surg today.* 2000;30:49-53.
  11. Atalay F, Odabasoglu F, Halici M, Cakir A, Cadirci E, Aslan A, et al. Gastroprotective and antioxidant effects of *Lobaria pulmonaria* and its metabolite rhizonyl alcohol on indomethacin-induced gastric ulcer. *Chem. Biodivers.* 2015;12(11):1756-67.
  12. Jia Y-T, Ma B, Wei W, Xu Y, Wang Y, Tang H-T, et al. Sustained activation of nuclear factor- $\kappa$ B by reactive oxygen species is involved in the pathogenesis of stress-induced gastric damage in rats. *Crit. Care Med.* 2007;35(6):1582-91.
  13. Khoshnoud MJ, Keshavarzi M, Mokhtari N, Sakhteman A, Derakhshanfar A, Rashedinia M. The protective effect of nortriptyline against gastric lesions induced by indomethacin and cold-shock stress in rats. *Iran. J. Toxicol.* 2020;14(3):155-64.
  14. Cohen G. Hochstein P: Glutathione peroxidase: The primary agent for the elimination of hydrogen peroxide in erythrocytes. *Biochemistry.* 1963;2:1420.
  15. Dringen R, Pawlowski PG, Hirrlinger J. Peroxide detoxification by brain cells. *J Neurosci RES.* 2005;79(1-2):157-65.
  16. Mahmoud MF, Nabil M, Abdo W, Abdelfattah MA, El-Shazly AM, El Kharrassi Y, et al. *Syzygium samarangense* leaf extract mitigates indomethacin-induced gastropathy via the NF- $\kappa$ B signaling pathway in rats. *Biomed. Pharmacother.* 2021;139:111675.
  17. Ramiro-Puig E, Casadesús G, Lee H-g, Zhu X, McShea A, Perry G, et al. Neuroprotective effect of cocoa flavonoids on in vitro oxidative stress. *Eur J Nutrition.* 2009;48:54-61.
  18. Cury DHB, Costa JE, Irika K, Mijji L, Garcez A, Buchiguel C, et al. Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease. *Dig. Dis. Sci.* 2008;53:2516-20.
  19. Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. *International J Mol Sci.* 2020;21(7):2346.
  20. Xie W, Huang X, Chen R, Chen R, Li T, Wu W, et al. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF- $\kappa$ B signaling pathways. *Drug Des Devel Ther.* 2019:2969-84.
  21. Tijani AS, Farombi EO, Olaleye SB. Mechanisms underlying the healing potentials of the methanol extract of *Chasmanthera dependens* stem on indomethacin-induced gastric ulcer. *Egypt. j. basic appl. sci.* 2021;8(1):17-31.
  22. Arab HH, Ashour AM, Alqarni AM, Arafa E-SA, Kabel AM. Camel milk mitigates cyclosporine-induced renal damage in rats: targeting p38/ERK/JNK MAPKs, NF- $\kappa$ B, and matrix metalloproteinases. *Biology.* 2021;10(5):442.
  23. Dröge W. Free radicals in the physiological control of cell function. *Physiol Rev.* 2002.
  24. Kortam MA, Ali BM, Fathy N. The deleterious effect of stress-induced depression on rat liver: Protective role of resveratrol and dimethyl fumarate via inhibiting the MAPK/ERK/JNK pathway. *J Biochem and Mol Toxicol.* 2021;35(1):e22627.
  25. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF- $\alpha$  agents—Comparison among therapeutic TNF- $\alpha$  antagonists. *Cytokine.* 2018;101:56-63.
  26. Sun Y, Oberley LW. Redox regulation of transcriptional activators. *Free Radic. Biol. Med.* 1996;21(3):335-48.
  27. Liu X, Chen Z, Mao N, Xie Y. The protective of hydrogen on stress-induced gastric ulceration. *Int. Immunopharmacol.* 2012;13(2):197-203.

28. Morgan M, Liu Z. gang, Liu ZG. Crosstalk of reactive oxygen species and NF- $\kappa$ B signaling Cell Res. 2011;21:103-15.
29. NATHAN C A. Beyondoxidativestress: an immunologist'sguidetoreactiveoxygenspecies. Nat Rev Immunol. 2013;13(5):349.
30. Akanda MR, Park B-Y. Involvement of MAPK/NF- $\kappa$ B signal transduction pathways: Camellia japonica mitigates inflammation and gastric ulcer. Biom Pharmacother. 2017;95:1139-46.
31. Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J. Gastroenterol. 2021;56:303-22.
32. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931-50.
33. Blair HA, Deeks ED. Infliximab biosimilar (CT-P13; infliximab-dyyb): a review in autoimmune inflammatory diseases. BioDrugs. 2016;30:469-80.
34. Sochal M, Krzywdzińska M, Gabryelska A, Talar-Wojnarowska R, Małeczka-Panas E. Efficiency and safety of one-year anti-TNF- $\alpha$  treatment in Crohn's disease: A Polish single-centre experience. Prz Gastroenterol. 2020;15(2):156-60.
35. Altintas N, Erboga M, Aktas C, Bilir B, Aydin M, Sengul A, et al. Protective effect of infliximab, a tumor necrosis factor- $\alpha$  inhibitor, on bleomycin-induced lung fibrosis in rats. Inflammation. 2016;39:65-78.
36. Guzel A, Kanter M, Guzel A, Pergel A, Erboga M. Anti-inflammatory and antioxidant effects of infliximab on acute lung injury in a rat model of intestinal ischemia/reperfusion. J. Mol. Histol. 2012;43:361-9.
37. Deng X, Wu W, Liang H, Huang D, Jing D, Zheng D, et al. Icariin prevents IL-1 $\beta$ -induced apoptosis in human nucleus pulposus via the PI3K/AKT pathway. Evid. Based Complementary Altern. Med. 2017;2017.
38. Dvoriantschikova G, Ivanov D. Tumor necrosis factor- $\alpha$  mediates activation of NF- $\kappa$ B and JNK signaling cascades in retinal ganglion cells and astrocytes in opposite ways. Eur. J. Neurosci. 2014;40(8):3171-8.
39. Reyes-García J, Flores-Soto E, Solís-Chagoyán H, Sommer B, Díaz-Hernández V, García-Hernández LM, et al. Tumor necrosis factor alpha inhibits L-type Ca<sup>2+</sup> channels in sensitized guinea pig airway smooth muscle through ERK 1/2 pathway. Mediators Inflamm. 2016;2016.
40. Wang Y, Cao J, Fan Y, Xie Y, Xu Z, Yin Z, et al. Artemisinin inhibits monocyte adhesion to HUVECs through the NF- $\kappa$ B and MAPK pathways in vitro. Int. J. Mol. Med. 2016;37(6):1567-75.
41. Zhan S, Rockey DC. Tumor necrosis factor  $\alpha$  stimulates endothelin-1 synthesis in rat hepatic stellate cells in hepatic wound healing through a novel IKK/JNK pathway. Exp Cell Res. 2011;317(7):1040-8.
42. Zhang Q, Wang J, Duan M-T, Han S-P, Zeng X-Y, Wang J-Y. NF- $\kappa$ B, ERK, p38 MAPK and JNK contribute to the initiation and/or maintenance of mechanical allodynia induced by tumor necrosis factor- $\alpha$  in the red nucleus. Brain research bulletin. 2013;99:132-9.
43. T ABDEL-RAHEEM I, Bamagous GA, Omran GA. NTI-ULCEROGENIC EFFECT OF GENISTEIN AGAINST INDOMETHACIN-INDUCED GASTRIC ULCER IN RATS. Asian J Pharm Clin Res. 2016:58-63.
44. El-Ashmawy NE, Khedr EG, El-Bahrawy HA, Selim HM. Nebivolol prevents indomethacin-induced gastric ulcer in rats. J Immunotoxicol. 2016;13(4):580-9.
45. Gomaa AM, Abd El-Mottaleb NA, Aamer HA. Antioxidant and anti-inflammatory activities of alpha lipoic acid protect against indomethacin-induced gastric ulcer in rats. Biomed Pharmacother. 2018;101:188-94.
46. Kirbas, A., Cure, M. C., Kalkan, Y., Cure, E., Tumkaya, L., Sahin, O. Z., Yuce, S., Kizilkaya, B., & Pergel, A. (2015). Effect of Infliximab on Renal Injury Due to Methotrexate in Rat. 9(3), 221–229.
47. Tasdemir C, Tasdemir S, Vardi N, Ates B,

- Parlakpınar H, Kati B, et al. Protective effect of infliximab on ischemia/reperfusion-induced damage in rat kidney. *Renal failure*. 2012;34(9):1144-9.
48. Reddy, K. R. (2012). Pylorus Ligation Induced Ulcers in Male Wistar Rats. 4(2), 2–7.
49. Drury R. Theory and practice of histological techniques. *J Clin Pathol*. 1983;36(5):609.
50. Majumder R, Datta M, Sarkar S, Chattopadhyay A, Bandyopadhyay D. The bacteriostatic property of melatonin targets peptic ulcer disease and cholangiocarcinoma. *Melatonin Res*. 2022;5(1):1-17.
51. Yandrapu H, Sarosiek J. Protective factors of the gastric and duodenal mucosa: an overview. *Curr. Gastroenterol. Rep*. 2015;17:1-8.
52. Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z. Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers. *Inflammation*. 2010;33:224-34.
53. Vickers NJ. Animal communication: when i'm calling you, will you answer too? *Current biology*. 2017;27(14):R713-R5.
54. Bai X, Guo X, Zhang F, Zheng L, Ding W, Yang S. Resveratrol combined with 17  $\beta$ -estradiol prevents IL-1  $\beta$  induced apoptosis in human nucleus pulposus via the PI3K/AKT/Mtor and PI3K/AKT/GSK-3  $\beta$  pathway. *J Invest Surg*. 2021;34(8):904-11.
55. Gisbert J, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. *Alimentary pharmacology & therapeutics*. 2007;25(1):19-37.
56. Freitas MO, Rodrigues MIDQ, Martins JODL, De Aguiar MT, Da Silva PMF, Silva PGDB, et al. TUMOR NECROSIS FACTOR (TNF)- $\alpha$  PLAYS A ROLE IN ORAL ULCERATION IN RATS. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2022;134(3):e198.
57. El Badawy SA, Ogaly HA, Abd-Elsalam RM, Azouz AA. Benzyl isothiocyanates modulate inflammation, oxidative stress, and apoptosis via Nrf2/HO-1 and NF- $\kappa$ B signaling pathways on indomethacin-induced gastric injury in rats. *Food Funct*. 2021;12(13):6001-13.
58. Chakraborty S, Yadav SK, Saha B, Tyagi M, Singh Rathee J, Chattopadhyay S. A bis-resorcinol resveratrol congener prevents indomethacin-induced gastric ulceration by inhibiting TNF- $\alpha$  as well as NF- $\kappa$ B and JNK pathways. *Free Radical Research*. 2019;53(6):596-610.
59. Ogaly HA, Alsherbiny MA, El Badawy SA, Abd-Elsalam RM, Li CG, Azouz AA. Gastroprotective effects and metabolomic profiling of Chasteberry fruits against indomethacin-induced gastric injury in rats. *Journal of Functional Foods*. 2021;86:104732.
60. Aziz RS, Siddiqua A, Shahzad M, Shabbir A, Naseem N. Oxyresveratrol ameliorates ethanol-induced gastric ulcer via downregulation of IL-6, TNF- $\alpha$ , NF- $\kappa$ B, and COX-2 levels, and upregulation of TFF-2 levels. *Biomedicine & pharmacotherapy*. 2019;110:554-60.
61. Chang YW, Jang JY, Kim NH, Lee JW, Lee HJ, Jung WW, et al. Interleukin-1B (IL-1B) polymorphisms and gastric mucosal levels of IL-1 $\beta$  cytokine in Korean patients with gastric cancer. *Int. J. Cancer*. 2005;114(3):465-71.
62. Güzel M, Sönmez MF, Baştuğ O, Aras NF, Öztürk AB, Küçükaydın M, et al. Effectiveness of lycopene on experimental testicular torsion. *J Pediatr Surg*. 2016;51(7):1187-91.
63. He B-S, Pan Y-Q, Xu Y-F, Zhu C, Qu L-L, Wang S-K. Polymorphisms in interleukin-1B (IL-1B) and interleukin 1 receptor antagonist (IL-1RN) genes associate with gastric cancer risk in the Chinese population. *Dig Dis Sci*. 2011;56:2017-23.
64. Rachmi CN, Agho KE, Li M, Baur LA. Stunting, underweight and overweight in children aged 2.0–4.9 years in Indonesia: prevalence trends and associated risk factors. *PloS one*. 2016;11(5):e0154756.
65. Tourani M, Habibzadeh M, Karkhah A, Shokri-Shirvani J, Barari L, Nouri HR.

- Association of TNF- $\alpha$  but not IL-1 $\beta$  levels with the presence of *Helicobacter pylori* infection increased the risk of peptic ulcer development. *Cytokine*. 2018;110:232-6.
66. Antonisamy P, Arasu MV, Dhanasekaran M, Choi KC, Aravinthan A, Kim NS, et al. Protective effects of trigonelline against indomethacin-induced gastric ulcer in rats and potential underlying mechanisms. *Food Funct*. 2016;7(1):398-408.
67. Tigari P, Janadri S, Madhu K, Taj N. Evaluation of anti-inflammatory effect of wedelolactone on indomethacin induced colitis in rats: involvement of IL-6/STAT3 pathway. *Biointerface Res Appl Chem*. 2021;12:2813-25.
68. Eltahir HM, Nazmy MH. Esomeprazole ameliorates CCl<sub>4</sub> induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers. *Biom Pharmacother*. 2018;97:1356-65.
69. Sofi SH, Nuraddin SM, Amin ZA, Al-Bustany HA, Nadir MQ. Gastroprotective activity of *Hypericum perforatum* extract in ethanol-induced gastric mucosal injury in Wistar rats: A possible involvement of H<sup>+</sup>/K<sup>+</sup> ATPase  $\alpha$  inhibition. *Heliyon*. 2020;6(10):e05249.
70. Danese S, Sans M, Scaldaferrì F, Sgambato A, Rutella S, Cittadini A, et al. TNF- $\alpha$  blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. *J Immunol*. 2006;176(4):2617-24.
71. Onda A, Murata Y, Rydevik B, Larsson K, Kikuchi S, Olmarker K. Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. *Spine*. 2004;29(17):1857-61.
72. Senousy SR, El-Daly M, Ibrahim AR, Khalifa MMA, Ahmed A-SF. Effect of celecoxib and infliximab against multiple organ damage induced by sepsis in rats: A comparative study. *Biomedicines*. 2022;10(7):1613.
73. Poutoglidou F, Pourzitaki C, Manthou ME, Samoladas E, Saitis A, Malliou F, et al. Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model. *Inflammopharmacology*. 2021;29(3):661-72.
74. Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. *Alex J Med*. 2018;54(4):287-93.
75. Gęgotek A, Skrzydlewska E. Biological effect of protein modifications by lipid peroxidation products. *Chem. Phys. Lipids*. 2019;221:46-52.
76. Grotto D, Maria LS, Valentini J, Paniz C, Schmitt G, Garcia SC, et al. Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification. *Quimica Nova*. 2009;32:169-74.
77. Gupta S, Finelli R, Agarwal A, Henkel R. Total antioxidant capacity—Relevance, methods and clinical implications. *Andrologia*. 2021;53(2):e13624.
78. Shin S, Jeong HM, Chung SE, Kim TH, Thapa SK, Song CH, et al. Simultaneous analysis of acetylcarnitine, proline, hydroxyproline, citrulline, and arginine as potential plasma biomarkers to evaluate NSAIDs-induced gastric injury by liquid chromatography–tandem mass spectrometry. *J Pharm Biomed Anal*. 2019;165:101-11.
79. Sabiu S, Garuba T, Sunmonu TO, Sulyman AO, Ismail NO. Indomethacin-induced gastric ulceration in rats: Ameliorative roles of *Spondias mombin* and *Ficus exasperata*. *Pharmaceut Biol*. 2016;54(1):180-6.
80. Abdelrahman AM, Al Suleimani YM, Ashique M, Manoj P, Ali BH. Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats. *Biom Pharmacother*. 2018;105:182-6.
81. Şahin TD, Gomez SS, Duruksu G, Yazir Y, Utkan T. Infliximab prevents dysfunction of the vas deferens by suppressing inflammation and oxidative

- stress in rats with chronic stress. *Life Sci.* 2020;250:117545.
82. Yu Y, Zhang Y, Zhang J, Guan C, Liu L, Ren L. Cantharidin-induced acute hepatotoxicity: the role of TNF- $\alpha$ , IKK- $\alpha$ , Bcl-2, Bax and caspase3. *J Appl Toxicol.* 2020;40(11):1526-33.
83. Zhou D, Yang Q, Tian T, Chang Y, Li Y, Duan L-R, et al. Gastroprotective effect of gallic acid against ethanol-induced gastric ulcer in rats: Involvement of the Nrf2/HO-1 signaling and anti-apoptosis role. *Biomed Pharmacother.* 2020;126:110075.
84. Ahmed MA, Mohanad M, Ahmed AA, Aboulhoda BE, El-Awdan SA. Mechanistic insights into the protective effects of chlorogenic acid against indomethacin-induced gastric ulcer in rats: Modulation of the cross talk between autophagy and apoptosis signaling. *Life Sci.* 2021;275:119370.
85. Taskiran AS, Ergul M, Gunes H, Ozturk A, Sahin B, Ozdemir E. The effects of proton pump inhibitors (pantoprazole) on pentylentetrazole-induced epileptic seizures in rats and neurotoxicity in the SH-SY5Y human neuroblastoma cell line. *Cell Mol Neurobiol.* 2021;41:173-83.
86. Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. *United European Gastroenterol. J.* 2018;6(7):1074-81.
87. Jiang Y, Liu D-W, Han X-Y, Dong Y-N, Gao J, Du B, et al. Neuroprotective effects of anti-tumor necrosis factor-alpha antibody on apoptosis following subarachnoid hemorrhage in a rat model. *J Clin NeuroSci.* 2012;19(6):866-72.
88. Saritemur M, Un H, Cadirci E, Karakus E, Akpınar E, Halıcı Z, et al. Tnf- $\alpha$  inhibition by infliximab as a new target for the prevention of glycerol-contrast-induced nephropathy. *Environ. Toxicol. Pharmacol.* 2015;39(2):577-88.
89. Sukhotnik I, Ben-Shahar Y, Pollak Y, Cohen S, Guz-Mark A, Shamir R. Anti-TNF- $\alpha$  Therapy Exerts Intestinal Anti-inflammatory and Anti-apoptotic Effects After Massive Bowel Resection in a Rat. *J. Pediatr. Gastroenterol. Nutr.* 2021;72(1):49-55.
90. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. *Gastroenterology.* 2008;135(1):41-60.
91. Ahmed RS, Suke SG, Seth V, Chakraborti A, Tripathi AK, Banerjee BD. Protective effects of dietary ginger (*Zingiber officinale* Rosc.) on lindane-induced oxidative stress in rats. *Phytother Res.* 2008;22(7):902-6.
92. Thomas P, Bansal A, Singh M, Shukla D, Saxena S. Preconditioning effect of cobalt chloride supplementation on hypoxia induced oxidative stress in male albino rats. *Biomed. Prev. Nutr.* 2011;1(2):84-90.
93. Ovalı F. Molecular and mechanical mechanisms regulating ductus arteriosus closure in preterm infants. *Front Pediatr.* 2020;8:516.
94. Bastaki SM, Chandranath IS, Singh J. The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits. *Mol Cell Biochem.* 2008;309:167-75.
95. Wen D, Li S, Jiang W, Zhu J, Liu J, Zhao S. miR-539 inhibits human colorectal cancer progression by targeting RUNX2. *Biomed Pharmacother.* 2017;95:1314-20.
96. Calleros L, Lasa M, Toro MJ, Chiloeches A. Low cell cholesterol levels increase NF $\kappa$ B activity through a p38 MAPK-dependent mechanism. *Cell Signal.* 2006;18(12):2292-301.
97. Yang S, Li F, Lu S, Ren L, Bian S, Liu M, et al. Ginseng root extract attenuates inflammation by inhibiting the MAPK/NF- $\kappa$ B signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. *J. Ethnopharmacol.* 2022;283:114739.
98. Zhang H-J, Liao H-Y, Bai D-Y, Wang Z-Q, Xie X-W. MAPK/ERK signaling pathway: A potential target for the treatment of

- intervertebral disc degeneration. *Biomed Pharmacother.* 2021;143:112170.
99. Fu Y, Wu Hq, Cui Hl, Li Yy, Li Cz. Gastroprotective and anti-ulcer effects of oxymatrine against several gastric ulcer models in rats: Possible roles of antioxidant, antiinflammatory, and prosurvival mechanisms. *Phytotherapy Res.* 2018;32(10):2047-58.
100. Holscher C, Gengler S, Gault VA, Harriott P, Mallot HA. Soluble beta-amyloid [25–35] reversibly impairs hippocampal synaptic plasticity and spatial learning. *Eur J Pharmacol.* 2007;561(1-3):85-90.
101. de Sousa Reis SD. Characterization of the Effects of Proton Pump inhibitors on bone Metabolism: in vitro study in cocultures of osteoclasts and Breast Cancer Cells and in Cultures of Osteoblasts. 2013.
102. Cordaro M, Siracusa R, D'Amico R, Genovese T, Franco G, Marino Y, et al. Role of Etanercept and Infliximab on Nociceptive Changes Induced by the Experimental Model of Fibromyalgia. *Int J Mol Sci.* 2022;23(11):6139.
103. Chen L-F, Greene WC. Shaping the nuclear action of NF- $\kappa$ B. *Nat. Rev. Mol. Cell Biol.* 2004;5(5):392-401.
104. Habib R, Wahdan SA, Gad AM, Azab SS. Infliximab abrogates cadmium-induced testicular damage and spermiotoxicity via enhancement of steroidogenesis and suppression of inflammation and apoptosis mediators. *Ecotoxicol. Environ. Saf.* 2019;182:109398.
105. Jamaluddin M, Wang S, Boldogh I, Tian B, Brasier AR. TNF- $\alpha$ -induced NF- $\kappa$ B/RelA Ser276 phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. *Cell signal.* 2007;19(7):1419-33.
106. Hebert KA, Bonnen MD, Ghebre YT. Proton pump inhibitors and sensitization of cancer cells to radiation therapy. *Frontiers Oncol.* 2022;12.
107. Huo X, Zhang X, Yu C, Zhang Q, Cheng E, Wang DH, et al. In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor- $\kappa$ B and activator protein-1. *Gut.* 2014;63(7):1042-52.
108. Song J-W, Seo C-S, Kim T-I, Moon O-S, Won Y-S, Son H-Y, et al. Protective effects of manassantin A against ethanol-induced gastric injury in rats. *Biol. Pharm. Bull.* 2016;39(2):221-9.
109. Dadsetan S, Balzano T, Forteza J, Cabrera-Pastor A, Taoro-Gonzalez L, Hernandez-Rabaza V, et al. Reducing peripheral inflammation with infliximab reduces neuroinflammation and improves cognition in rats with hepatic encephalopathy. *Frontiers Mol NeuroSci.* 2016;9:106.
110. Younis NN, Mohamed HE, Shaheen MA, Abdelghafour AM, Hammad SK. Inactivation of Wnt/ $\beta$ -catenin/renin angiotensin axis by tumor necrosis factor- $\alpha$  inhibitor, infliximab, ameliorates CKD induced in rats. *Biochem Pharmacol.* 2021;185:114426.